Allianz Asset Management Gmb H Allogene Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$4.53 - $6.74 $97,848 - $145,584	21,600 Added 103.85%	42,400 $210,000
Q1 2023 May 11, 2023	BUY	$4.92 - $8.21 $102,336 - $170,768	20,800 New	20,800 $102,000
Q3 2022 Nov 08, 2022	SELL	$10.32 - $17.28 $251,653 - $421,372	-24,385 Reduced 53.85%	20,900 $226,000
Q1 2022 May 13, 2022	SELL	$7.65 - $15.29 $71,145 - $142,197	-9,300 Reduced 17.04%	45,285 $412,000
Q4 2021 Feb 11, 2022	BUY	$13.13 - $24.52 $507,080 - $946,962	38,620 Added 241.9%	54,585 $819,000
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $375,017 - $571,547	15,965 New	15,965 $416,000
Q4 2020 Feb 16, 2021	SELL	$25.24 - $43.45 $451,669 - $777,537	-17,895 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$32.38 - $44.96 $53,200 - $73,869	-1,643 Reduced 8.41%	17,895 $675,000
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $359,303 - $1.06 Million	19,538 New	19,538 $837,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.